Cite

HARVARD Citation

    Zhou, H. et al. (2020). Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children. Journal of asthma. pp. 87-94. [Online]. 
  
Back to record